) collaboration partner, GlycoMimetics, Inc. recently presented
positive top-line phase II results on its sickle cell disease
candidate, GMI-1070. The randomized, double-blind,
placebo-controlled study was conducted in patients with sickle
cell disease experiencing vaso-occlusive crisis.
The study was conducted to evaluate the efficacy, safety and
pharmacokinetics of GMI-1070. Results showed that patients
receiving GMI-1070 demonstrated a reduction in the duration of
vaso-occlusive crisis, reduction in the length of hospital stay
and the use of narcotic pain relief.
Improvement was observed in both adult and pediatric patients
with the occurrence of adverse event rates being comparable to
placebo. Detailed study results will be presented at a scientific
We note that Pfizer and GlycoMimetics had entered into the
collaboration agreement in Oct 2011. Per the terms of the
agreement, Pfizer will be responsible for the further development
and commercialization of GMI-1070. GlycoMimetics may receive up
to $340 million in the form of upfront and milestone payments. It
is also entitled to royalties on sales.
GMI-1070 has orphan drug as well as fast track status in the
US. Sickle cell disease, one of the most prevalent genetic
disorders in the US, affects more than 80,000 people.
Pfizer currently carries a Zacks Rank #3 (Hold). While
near-term earnings will be driven by cost cutting efforts and
share repurchases, longer-term growth will depend on the success
of drug development. Pfizer's pipeline needs to deliver given the
Lipitor loss of exclusivity and the upcoming loss of exclusivity
on additional products in the next few years.
Currently, companies like
Catalyst Pharmaceutical Partners Inc.
Astellas Pharma, Inc.
) look attractive in the pharma space. While both UCB and
Catalyst Pharma are Zacks Rank #1 (Strong Buy) stocks, Astellas
is a Zacks Rank #2 (Buy) stock.
ASTELLAS PHARMA (ALPMY): Get Free Report
CATALYST PHARMA (CPRX): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.